IPSC Century Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850119 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,556.5%
TTM net income YoY92.4%
TTM EPS YoY91.3%
Revenue 3-yr CAGR175.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15.8%
Net margin-8.8%
FCF margin-95.9%
EBITDA margin-3.8%
Returns
ROE-6.0%
ROA-3.3%
ROIC (approx.)-13.8%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio5.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income10.85x
Accruals ratio32.7%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $109.16M | $6.59M |
| R&D expense | $95.67M | $107.24M |
| SG&A expense | $24.00M | $33.16M |
| Operating income | -$17.27M | -$138.14M |
| Pretax income | -$9.65M | -$124.78M |
| Income tax | -$68,000 | $1.79M |
| Net income | -$9.58M | -$126.57M |
| EBITDA | -$4.17M | -$124.83M |
| EPS (basic) | -0.14 | -1.61 |
| EPS (diluted) | -0.14 | -1.61 |
| Weighted avg. shares (diluted) | 86.56M | 78.65M |
| Balance sheet | ||
| Cash & equivalents | $61.85M | $61.21M |
| Short-term investments | $55.26M | $130.85M |
| Current assets | $120.77M | $194.05M |
| PP&E, net | $50.03M | $62.14M |
| Intangibles | $34.20M | $34.20M |
| Total assets | $223.70M | $353.22M |
| Current liabilities | $20.23M | $129.78M |
| Total liabilities | $64.77M | $191.85M |
| Shareholders' equity | $158.94M | $161.36M |
| Shares outstanding | 87.52M | 85.84M |
| Cash flow statement | ||
| Operating cash flow | -$103.88M | -$110.14M |
| Capital expenditure | $848,000 | $154,000 |
| Free cash flow | -$104.72M | -$110.29M |
| Investing cash flow | $107.50M | $47.48M |
| Financing cash flow | $173,000 | $74.56M |
| Depreciation & amortization | $13.10M | $13.30M |
| Stock-based compensation | $6.84M | $12.69M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.